We are actively exploring the potential of disrupting the immunosuppressive processes that promote tumor growth and bolstering the immune system's power to fight cancer.
See how targeting CD20 and CD3 can harness the immune system against cancer.
Learn about the potential of simultaneous binding CEA on tumor cells and CD3 on T cells.
Investigate the PD-L1 pathway and cancer immune evasion.
Learn about targeting the novel TIGIT immune checkpoint and anti-tumor immunity.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.